-
-
-
-
-
-
-
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
-
-
-
-
-
-
-
Bristol Myers Squibb's RYZ101 meets primary endpoint in phase 3 GEP-NET trial
-
-
-
-
-
-
-
FDA approves Bristol Myers Squibb's Camzyos for pediatric oHCM
-
-
-
-
-
-
-
Buy the pullback in this large pharma stock: UBS
-
-
-
-
-
-
-
Bristol Myers Squibb plans $2.3B manufacturing campus in Houston
-
-
-
-
-
-
-
Bristol Myers Squibb Reports Second Quarter Financial Results for 2026
-
-
-
-
-
-
-
Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Brea
-
1,239,435 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


